HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.

Plum, Patrick Sven; Gebauer, Florian; Krämer, Max; Alakus, Hakan; Berlth, Felix; Chon, Seung-Hun; Schiffmann, Lars; Zander, Thomas; Büttner, Reinhard; Hölscher, Arnulf Heinrich; Bruns, Christiane Josephine; Quaas, Alexander; Loeser, Heike

Plum, Patrick Sven; Gebauer, Florian; Krämer, Max; Alakus, Hakan; Berlth, Felix; Chon, Seung-Hun; Schiffmann, Lars; Zander, Thomas; Büttner, Reinhard; Hölscher, Arnulf Heinrich; Bruns, Christiane Josephine; Quaas, Alexander; Loeser, Heike.

Afiliación

Plum PS; Department of General, Visceral and Cancer Surgery, University Hospital Cologne, Cologne, Germany.
Gebauer F; Gastrointestinal Cancer Group Cologne (GCGC), University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Krämer M; Department of General, Visceral and Cancer Surgery, University Hospital Cologne, Cologne, Germany.
Alakus H; Gastrointestinal Cancer Group Cologne (GCGC), University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Berlth F; Institute of Pathology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Chon SH; Department of General, Visceral and Cancer Surgery, University Hospital Cologne, Cologne, Germany.
Schiffmann L; Gastrointestinal Cancer Group Cologne (GCGC), University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Zander T; Department of General, Visceral and Cancer Surgery, University Hospital Cologne, Cologne, Germany.
Büttner R; Department of General, Visceral and Cancer Surgery, University Hospital Cologne, Cologne, Germany.
Hölscher AH; Department of General, Visceral and Cancer Surgery, University Hospital Cologne, Cologne, Germany.
Bruns CJ; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
Quaas A; Gastrointestinal Cancer Group Cologne (GCGC), University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Loeser H; Institute of Pathology, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

BMC Cancer ; 19(1): 38, 2019 Jan 08.

Article en En | MEDLINE | ID: mdl-30621632

Asunto(s)

Adenocarcinoma/genética; Biomarcadores de Tumor/genética; Neoplasias Esofágicas/genética; Pronóstico; Receptor ErbB-2/genética; Adenocarcinoma/epidemiología; Adenocarcinoma/patología; Adenocarcinoma/cirugía; Adulto; Anciano; Proliferación Celular/genética; Neoplasias Esofágicas/epidemiología; Neoplasias Esofágicas/patología; Neoplasias Esofágicas/cirugía; Esofagectomía; Unión Esofagogástrica/patología; Femenino; Amplificación de Genes/genética; Regulación Neoplásica de la Expresión Génica/genética; Humanos; Hibridación Fluorescente in Situ; Metástasis Linfática; Masculino; Persona de Mediana Edad; Estadificación de Neoplasias; Análisis de Matrices Tisulares

Palabras clave

Esophageal adenocarcinoma (EAC); Fluorescence-in-situ-hybridization (FISH); HER2/neu (ERBB2); Immunohistochemistry; Prognosis; Tissue microarray (TMA)

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pronóstico / Neoplasias Esofágicas / Adenocarcinoma / Biomarcadores de Tumor / Receptor ErbB-2 Tipo de estudio: Guideline / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google